open access
Trabectedin in the treatment of patients with soft tissue sarcoma
open access
Abstract
Soft tissue sarcomas (STS) are rare malignant tumours derived from connective tissue. They constitute about 1% of malignancies occurring in adults. We distinguish over 60 subtypes of soft tissue sarcoma, each with a unique clinical course and a diversified response to systemic treatment. The prognosis for patients with locally advanced, unresectable or metastatic disease remains poor. For years, doxorubicin — used alone or in combination with ifosfamide — has been the basis of treatment for these patients. Trabectedin is a relatively new molecule registered in the treatment of patients diagnosed with STS. The drug was originally obtained from marine tunicates (Ecteinascidia turbinata), currently it is obtained semi-synthetically. So far, a number of potential mechanisms of trabectedin have been described, including DNA-binding, disruption of DNA repair mechanisms and cell cycle, as well as effects on transcription factors and the tumour microenvironment. The aim of the following review is to summarize the current knowledge on the efficacy and safety of trabectedin in the treatment of patients diagnosed with STS.
Abstract
Soft tissue sarcomas (STS) are rare malignant tumours derived from connective tissue. They constitute about 1% of malignancies occurring in adults. We distinguish over 60 subtypes of soft tissue sarcoma, each with a unique clinical course and a diversified response to systemic treatment. The prognosis for patients with locally advanced, unresectable or metastatic disease remains poor. For years, doxorubicin — used alone or in combination with ifosfamide — has been the basis of treatment for these patients. Trabectedin is a relatively new molecule registered in the treatment of patients diagnosed with STS. The drug was originally obtained from marine tunicates (Ecteinascidia turbinata), currently it is obtained semi-synthetically. So far, a number of potential mechanisms of trabectedin have been described, including DNA-binding, disruption of DNA repair mechanisms and cell cycle, as well as effects on transcription factors and the tumour microenvironment. The aim of the following review is to summarize the current knowledge on the efficacy and safety of trabectedin in the treatment of patients diagnosed with STS.
Keywords
trabectedin, soft tissue sarcomas, leiomyosarcoma, liposarcoma
About this articleTitle
Trabectedin in the treatment of patients with soft tissue sarcoma
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
127-131
Published online
2018-11-26
Page views
840
Article views/downloads
806
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2018;68(3):127-131.
Keywords
trabectedin
soft tissue sarcomas
leiomyosarcoma
liposarcoma
Authors
Hanna Koseła-Paterczyk
Piotr Rutkowski